- The first shipment of SMART inhalers, 10,000 cartridges and QR codes arrived in the UK for the clinic’s pilot run
- Due to the large scale of the clinical trial, RYAH developed a custom software solution for the clinic
- In the UK the medical cannabis market is expected to reach $1.3 billion by 2024, and 1% of the population could be medical cannabis patients by 2028
RYAH Group (CSE: RYAH), a connected device and big data and technology company, has completed its initial shipment to a major international clinic conducting a study in the UK on the safety and efficacy of cannabis and hemp for the treatment of chronic pain (https://ibn.fm/Q9QOT). The first shipment will be used by the clinic in a pilot run. It consisted of RYAH’s Smart Dry Herb Inhalers, including 10,000 RYAH Cartridges and QR Codes. The complete order estimated to be tens of thousands of dry herb vaporizers and several million RYAH proprietary dry herb cartridges, to be purchased over five years (https://ibn.fm/RJncA). This study is one of the world’s largest and most comprehensive clinical trials in plant-based medicine.
When the purchase order was first announced, Jordan Medley, Director of Product Operations at RYAH stated, “We are thrilled to create a custom solution for our clinic partner that helps facilitate the unique needs of their study. By giving the clinic the ability to a) prescribe a specific amount of dry herb medicine in pre-filled, tamper proof cartridges, and b) set a specific temperature and dose for each of their patients in their very own app, it improves the integrity of the study by removing key variables that could drastically influence the effects that their patients experience.”
Due to the large scale of the study, RYAH developed a custom software solution for the clinic using OAuth API-integration to protect the participants’ privacy while also enabling fully integrated patient feedback and data collection platform. This will allow for the large scale and reduce data collection and interpretation variables for dose measurement and patient feedback.
UK clinics predominantly focus on CBPMHs as a treatment for: multiple sclerosis, chemotherapy-induced nausea, treatment-resistant childhood epilepsy, chronic pain, and weight loss associated with HIV/AIDS. According to Prohibition Partners, up to 1% of the UK population could be medical cannabis patients by 2028. The total legal cannabis market is anticipated to reach $3 billion by 2024, with the medicinal cannabis market taking up $1.3 billion of that estimate (https://ibn.fm/0UaVu). The European cannabis investment sector has turned its attention to the UK market with London playing host to the annual Cannabis Europa conference and seeing the arrival of numerous consultancies, market research, and cannabis-focused finance groups.
“We are pleased to bring RYAH’s IoT device and integrated data solutions to the United Kingdom, providing a new level of session accuracy, patient feedback consistency, and data integrity to the clinical framework in plant-based medicine research. We continue to evolve our product and software solutions to help clinicians and researchers unlock breakthroughs in clinical research and analytics,” said Gregory Wagner, CEO of RYAH Group, Inc.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
